In 2021, the 30.7 million beneficiaries accounted for over $2 billion in payments for the 101 generic drugs. Under the ...

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s ...

Batoclimab is an anti-FcRn treatment being developed for a range of autoimmune diseases and active thyroid eye disease (TED).

Find insights on AstraZeneca, Incyte and more in the latest Market Talks from the health-care sector.

Given these promising results and a strong scientific rationale, combined with LX-101’s novel mechanism of action and prior positive clinical experience in oncology, Lirum is planning new clinical ...

THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe ...

TSH receptor bioassays (TSAb) that use cells (FRTL-5 cells, or more recently CHO transfected with human TSH receptor) to detect thyroid stimulating immunoglobulins (TSAb) that either stimulate ...

Among the scariest of these fears is that GLP-1 drugs may cause certain types of thyroid cancer. The risk is relevant enough that the Food and Drug Administration has long required GLP-1 drugs to ...

Batoclimab receives Orphan Drug Designation in Japan, advancing treatment for active Thyroid Eye Disease (TED). Batoclimab, subcutaneous formulation, offers the potential for at-home administration, ...